A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers.

Trial Profile

A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2011

At a glance

  • Drugs Ketoconazole; Tofacitinib
  • Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Feb 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 16 Feb 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top